Orthocell has reported promising interim results from a new study which investigated the role of sutures in nerve repair.
The study showed that its flagship "Remplir" product delivers superior outcomes compared with the traditional suture-only method/ and highlights Remplir’s potential to redefine the nerve repair market.
Orthocell’s CEO and MD, Paul Anderson, said: “These Study results provide key data to support the U.S. product sales roll out and rapid market adoption and will be a cornerstone of our US medical education efforts.”
#Orthocell #Remplir #NerveRepair #RegenerativeMedicine #MedicalInnovation #ClinicalStudy #USHealthcare #PeripheralNerveInjury #BiotechAustralia #MedTech #SuturelessRepair #PaulAnderson